<DOC>
	<DOCNO>NCT02650973</DOCNO>
	<brief_summary>This randomize , single-blind , 3-period crossover study healthy subject assess PK , PD , safety ( include immunogenicity ) single 6mg subcutaneous injection CHS-1701 ( Coherus pegfligrastim ) 6mg SC dose Neulasta ( pegfilgrastim ) give period .</brief_summary>
	<brief_title>Study Assess Pharmacokinetic Pharmacodynamic Bioequivalence CHS-1701 With Neulasta</brief_title>
	<detailed_description>This randomize , single-blind , 3-period crossover study healthy subject assess PK , PD , safety ( include immunogenicity ) single 6mg subcutaneous injection CHS-1701 6mg SC dose Neulasta give period . The screening period may occur 28 day prior confinement period . After screen , eligible subject randomly assign one three possible treatment sequence . Treatments space less 28 day .</detailed_description>
	<criteria>1 . Adult male female age 18 45 inclusive 2 . Body weight &gt; 50 kg ( 110 lb . ) body mass index 18 28 kg/m2 inclusive 3 . Medically healthy clinically insignificant finding base medical history , 12lead ECG , physical examination 4 . Negative urine pregnancy test woman childbearing potential 1 . Previous exposure pegfilgrastim filgrastim 2 . Current previous cancer , diabetes , clinically significant cardiovascular , metabolic , endocrine , renal , hepatic , gastrointestinal , hematologic , respiratory , dermatological , neurological , gynecologic , psychiatric , disorder 3 . History chronic acute respiratory illness within past 3 month 4 . Positive urine drug alcohol screen unwillingness abstain alcohol recreational drug duration study participation 5 . No prescription nonprescription drug study 6 . Participation investigational clinical study within 30 day prior screen 7 . History know clinically significant drug and/or food allergy , include allergic reaction latex</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>